Literature DB >> 20125036

Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients.

Max J Hilz1, Harald Marthol, Stefan Schwab, Edwin H Kolodny, Miroslaw Brys, Brigitte Stemper.   

Abstract

OBJECTIVE: Fabry patients have autonomic dysfunction but usually do not present clinically overt signs of orthostatic dysregulation. This study evaluated orthostatic regulation and baroreflex sensitivity (BRS) in untreated Fabry patients and possible baroreflex improvement with enzyme replacement therapy (ERT).
METHODS: In 22 Fabry patients (aged 28W8 years), we assessed electrocardiographic RR intervals (RRIs), SBP, DBP and respiratory frequency, in supine and standing position, before and after 18 (11 patients) or 23 months (11 patients) of biweekly alpha-galactosidase A infusions (1.0 mg/kg agalsidase beta). We determined spectral powers of mainly sympathetically mediated low-frequency (0.04-0.15 Hz) and parasympathetically mediated high-frequency (0.15-0.5 Hz) RRI fluctuations, and sympathetic low-frequency powers of blood pressure fluctuations. We normalized RRI powers by relating low-frequency and high-frequency powers to total powers (low-frequency + high-frequency powers), assessed the RRI low-frequency/high-frequency ratio reflecting sympathicovagal balance. As a measure of BRS, we used the alpha-index, obtained as square root of the ratio between powers of simultaneous spectral analyses of spontaneous low-frequency variabilities in RRIs and SBP (coherence>0.5). We compared parameters in supine and standing position of untreated and treated patients with those of 15 healthy age-matched (27+/-5 years) men (repeated-measure analysis of variance, significance at P<0.05).
RESULTS: Supine biosignals were similar in all groups. Upon standing, RRIs were lower in controls and patients after ERT than in patients before ERT (P<0.05); normalized RRI high-frequency powers as well as BRS decreased, whereas DBP, low-frequency/high-frequency ratios and sympathetic low-frequency powers of SBP increased in controls and treated patients only (P<0.05).
CONCLUSION: Reduced increase in heart rate, blood pressure and sympathetic activation, and limited cardiovagal withdrawal and BRS adjustment seen in untreated Fabry patients upon standing normalized after 18 and 23 months of ERT demonstrating improved baroreflex function, which, in turn, is an established parameter of improved disease prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20125036     DOI: 10.1097/HJH.0b013e328336a077

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.

Authors:  Max J Hilz; Ruihao Wang; Carmen de Rojas Leal; Mao Liu; Francesca Canavese; Sankanika Roy; Katharina M Hösl; Klemens Winder; De-Hyung Lee; Ralf A Linker
Journal:  Ther Adv Neurol Disord       Date:  2017-01-06       Impact factor: 6.570

2.  Poikilothermia in a 38-year-old Fabry patient.

Authors:  Marieke Biegstraaten; Ivo N van Schaik; Carla E M Hollak; Wouter Wieling; Gabor E Linthorst
Journal:  Clin Auton Res       Date:  2010-12-15       Impact factor: 4.435

Review 3.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

Review 4.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

Review 5.  Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

Authors:  Regina El Dib; Huda Gomaa; Alberto Ortiz; Juan Politei; Anil Kapoor; Fellype Barreto
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

6.  Cerebral lesion correlates of sympathetic cardiovascular activation in multiple sclerosis.

Authors:  Klemens Winder; Ralf A Linker; Frank Seifert; Ruihao Wang; De-Hyung Lee; Tobias Engelhorn; Arnd Dörfler; Kilian Fröhlich; Max Hilz
Journal:  Hum Brain Mapp       Date:  2019-08-12       Impact factor: 5.038

7.  Altered pupillary light responses are associated with the severity of autonomic symptoms in patients with Fabry disease.

Authors:  Gulfidan Bitirgen; Kultigin Turkmen; Nazmi Zengin; Rayaz A Malik
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

8.  Brain Angiotensin II Type 1 Receptor Blockade Improves Dairy Blood Pressure Variability via Sympathoinhibition in Hypertensive Rats.

Authors:  Takuya Kishi; Yoshitaka Hirooka; Kenji Sunagawa
Journal:  Int J Hypertens       Date:  2015-03-30       Impact factor: 2.420

9.  Valsalva maneuver unveils central baroreflex dysfunction with altered blood pressure control in persons with a history of mild traumatic brain injury.

Authors:  Max J Hilz; Mao Liu; Julia Koehn; Ruihao Wang; Fabian Ammon; Steven R Flanagan; Katharina M Hösl
Journal:  BMC Neurol       Date:  2016-05-04       Impact factor: 2.474

10.  Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.

Authors:  David G Warnock; Christie P Thomas; Bojan Vujkovac; Ruth C Campbell; Joel Charrow; Dawn A Laney; Leslie L Jackson; William R Wilcox; Christoph Wanner
Journal:  J Med Genet       Date:  2015-10-21       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.